These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 18849763)

  • 1. The association between a tiered pharmacy benefit plan and medication usage, health status, and disability absence days--one employer's experience.
    Burton WN; Chen CY; Schultz AB; Edington DW
    J Occup Environ Med; 2008 Oct; 50(10):1176-84. PubMed ID: 18849763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
    Johnson JT; Neill KK; Davis DA
    J Manag Care Pharm; 2011 Apr; 17(3):200-12. PubMed ID: 21434697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Community pharmacy and mail order cost and utilization for 90-day maintenance medication prescriptions.
    Khandelwal N; Duncan I; Rubinstein E; Ahmed T; Pegus C
    J Manag Care Pharm; 2012 Apr; 18(3):247-55. PubMed ID: 22468733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence and adherence with urinary antispasmodic medications among employees and the impact of adherence on costs and absenteeism.
    Kleinman NL; Odell K; Chen CI; Atkinson A; Zou KH
    J Manag Care Spec Pharm; 2014 Oct; 20(10):1047-56. PubMed ID: 25278327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Member satisfaction related to self-reported cost share and difficulty in obtaining prescription drugs in a university pharmacy benefit plan.
    Nau DP; Chi C; Mallya U; Kirking DM
    J Manag Care Pharm; 2007 Mar; 13(2):135-41. PubMed ID: 17330974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects on the cost and utilization of proton pump inhibitors from adding over-the counter omeprazole to drug benefit coverage in a state employee health plan.
    Harris BN; West DS; Johnson J; Hong SH; Stowe CD
    J Manag Care Pharm; 2004; 10(5):449-55. PubMed ID: 15369428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Employer-Sponsored Onsite Pharmacy and Condition Management Programs on Medication Adherence.
    Aguilar KM; Hou Q; Miller RM
    J Manag Care Spec Pharm; 2015 Aug; 21(8):670-7. PubMed ID: 26233539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of Low-Cost Generic Program Use in a Nationally Representative Cohort of Privately Insured Adults.
    Pauly NJ; Brown JD
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1162-70. PubMed ID: 26679965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a comprehensive employee wellness program at an organization with a consumer-directed health plan.
    Burton WN; Chen CY; Li X; Schultz AB; Kasiarz D; Edington DW
    J Occup Environ Med; 2014 Apr; 56(4):347-53. PubMed ID: 24709759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of the use and costs of physician office visits and prescription drugs to travel distance and increases in member cost share.
    Cecil WT; Barnes J; Shea T; Coulter SL
    J Manag Care Pharm; 2006 Oct; 12(8):665-76. PubMed ID: 17269845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of medication therapy management services for patients with cardiovascular disease in a self-insured employer health plan.
    Wittayanukorn S; Westrick SC; Hansen RA; Billor N; Braxton-Lloyd K; Fox BI; Garza KB
    J Manag Care Pharm; 2013 Jun; 19(5):385-95. PubMed ID: 23697476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of mail-order with community pharmacy in plan sponsor cost and member cost in two large pharmacy benefit plans.
    Johnsrud M; Lawson KA; Shepherd MD
    J Manag Care Pharm; 2007 Mar; 13(2):122-34. PubMed ID: 17330973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy.
    Yokoyama K; Yang W; Preblick R; Frech-Tamas F
    J Manag Care Pharm; 2007 Apr; 13(3):235-44. PubMed ID: 17407390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications.
    Gleason PP; Starner CI; Gunderson BW; Schafer JA; Sarran HS
    J Manag Care Pharm; 2009 Oct; 15(8):648-58. PubMed ID: 19803554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescription drug costs and the generic dispensing ratio.
    Liberman JN; Roebuck MC
    J Manag Care Pharm; 2010 Sep; 16(7):502-6. PubMed ID: 20726679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid Program.
    Simeone JC; Marcoux RM; Quilliam BJ
    J Manag Care Pharm; 2010 Jun; 16(5):317-28. PubMed ID: 20518584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
    Bergeson JG; Worley K; Louder A; Ward M; Graham J
    J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association of antidepressant medication adherence with employee disability absences.
    Burton WN; Chen CY; Conti DJ; Schultz AB; Edington DW
    Am J Manag Care; 2007 Feb; 13(2):105-12. PubMed ID: 17286530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health benefit costs and absenteeism due to insomnia from the employer's perspective: a retrospective, case-control, database study.
    Kleinman NL; Brook RA; Doan JF; Melkonian AK; Baran RW
    J Clin Psychiatry; 2009 Aug; 70(8):1098-104. PubMed ID: 19758521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humanistic, utilization, and cost outcomes associated with the use of botulinum toxin for treatment of refractory migraine headaches in a managed care organization.
    Mitchell MP; Schaecher K; Cannon HE; Speckman M
    J Manag Care Pharm; 2008 Jun; 14(5):442-50. PubMed ID: 18597573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.